Member Info for Soupdragon78

UK patent is covered under the European Patent.

Anyways.... todays fun.

The EU patent for NXP002 was published today in the European Patent Bulletin, which means its fully up and running.

See page 995.

https://www.epo.org/bulletin/downloads/2024/bulletin2424.pdf

Website doesn't really matter in cases like NFX, whether small private investors decide to buy or not doesn't bear any influence on whether the company outlicences or not.

Value is only added by doing a deal, nothing else.

The EU patent for NXP002 gets published and takes effect on the 12th (Wednesday), so we'll see if the company is bothered about news by the end of the week. Absolutely no reason to not tell the market.

Sorry to hear they blocked you out TH. In my view user controlled groups like telegram are self defeating anyway, very little constructive ever comes out of them. Its just a power trip for those with admin rights to ban folk that don't fit their narrative.

Thats why I like LSE where posters can't even edit their own posts, let alone delete them or ban people.

Understood Older, to me it would be about minimising risk of delay to the process or worse.

Its just like a developer would never submit a planning application without a pre-application meeting to understand initial thoughts and how receptive those who make the decisions are to the proposals.

Also from the EMA website.

"EMA strongly encourages sponsors to request a pre-submission meeting with the Agency prior to filing an application. Pre-submission meetings usually take place via teleconference, unless the sponsor has a strong preference to come to EMA in person.

If a sponsor feels they could benefit from a preliminary discussion before the submission of an orphan drug application, they can request a pre-submission meeting/teleconference at least two months prior to their planned submission date via the IRIS portal. This should allow enough time for the organisation and any amendment of the application as recommended by EMA.

Sponsors should create an initial draft application for orphan designation before creating the application for the pre-submission discussion. These are two separate submissions to be made in the IRIS system. The draft submission for orphan designation should be populated with the relevant data and documents, but not submitted, at least one week before the pre-submission meeting date.

Pre-submission meetings are useful since the evaluation process has a fixed duration of 90 days and cannot be lengthened to accommodate for the lack of data or other omissions in the application. Experience has shown that they have a positive impact on the success rate of the applications."

FX, yes he apparently said they would go for orphan status, he didn't say when they would though.

This isn't like when applied for your bus pass, you have to pull a lot of information together and get it right. I would envisage they need to employ someone to do so and it would take a period of time.

As I've mentioned before, the guidance says that a company should have a pre-submission meeting at least two months before submitting.

So even if they started the process in early March, they may only be getting to the point where they are in a good position to apply.

I'll go back to my point about Dan's telegram comment, from what was reported he apparently only said they were thinking about orphan designation application and leaning towards EU side.

I would expect they would need someone to pull together the documentation on their behalf and submit. So I doubt the application went in straight away, if at all yet.

Milk and two please.

Lucky Dan.

I hear you Older, I would love it to be NXP002.

But also from your transcript of Dans telegram conversation....

"We also don’t have orphan status. Every other asset out there has got orphan status already. To compete, I think personally we need that. Ideally from the European vs the US. If we go for European orphan designation, we have to present our existing data and rationale. If it’s accepted, it acts like a badge of honour – independent validation we’ve got potential – so drug companies like it. "

Note.

'If we go for European Designation....'

It sounds like they were deliberating whether to go for US or EU designation.

The company has said that its a likely candidate for a few years now.

I'm saying its 'a long shot' with the agenda saying that they are discussing a 'Treatment of idiopathic pulmonary fibrosis'

As in, the chances of this very brief phrase being NXP002 are a long shot. Its kind of like Gareth Southgate saying they are 'discussing a midfielder' to be in the England squad and people then saying he must mean a specific player. Quite a long shot at guessing who he means from such a brief statement.

Thanks for the link Older, its a long shot but fingers crossed.

Idle hands and all that....

Https://patentscope.wipo.int/search/docs2/wipocase/EP328059213/pdf/HwSVpm9FgLI1qN5zXiL1n4jT4flhPsF_EOYI78Dn52TleNlil-DQx2A8o2zt7LfbpXJnc4eis77u7iPDrlObu_WKp34t81rqjaP-8q5Sfg-Ivq_aTUmPYYleXjLHF4VIM6HqSfQS9MymCKjSXR_EL0mhzVjFRXHiiaRI234gpDQM8N8i7DBVzRAhr80pj_Ey4hsvPaB_GCUOa-EclgG-P7eP-ZmTXMy9BBx0aiYlgVhwyLlVIcQhbO9uQG-Ra7mk2kARkXMfAiSeUkRNBkaF2A?filename=Decision_to_grant_a_European_patent.pdf

Thanks, I’ll come back when you’ve got something constructive to add to the thread.

Not tetchy, just surprised that you asked such a basic question or maybe I should just assume it was wilful ignorance.

Ok. maybe something you should have considered before looking at the stock market.

You really don’t understand why companies hold assets in subsidiaries?

Why should they be registered with the plc?